Sort   by:  
 Page size 
GenomicsIdentification of drivers and therapeutic vulnerabilities in anti-androgen resistant prostate cancer cells
Identification of drivers and therapeutic vulnerabilities in anti-androgen resistant prostate cancer cells
PRJNA540539 | ENA
TranscriptomicsLNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens
The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Using the LnCaP/AR xenograft model, we identified induction of glucocorticoid receptor (GR) expression as a common feature of drug resistant tumors. From a resistant xenograft tumor...
ORGANISM(S): Homo sapiens 
2013-12-27 | E-GEOD-51873 | biostudies-arrayexpress
GenomicsCaloric restriction enhances the activity of anti-androgen therapy by inhibiting androgen receptor translation in prostate cancer
Caloric restriction enhances the activity of anti-androgen therapy by inhibiting androgen receptor translation in prostate cancer
PRJNA1089192 | ENA
GenomicsAnti-proliferative, Apoptosis and Anti-migration Properties on Androgen-independent Human Prostate Cancer by a Diarylpentanoid, MS13.
Anti-proliferative, Apoptosis and Anti-migration Properties on Androgen-independent Human Prostate Cancer by a Diarylpentanoid, MS13.
PRJNA743282 | ENA
TranscriptomicsIdentification of drivers and therapeutic vulnerabilities in anti-androgen resistant prostate cancer cells
Inhibition of the androgen receptor (AR) by anti-androgens is the standard treatment for castration resistant prostate cancer (CRPC), but it inevitably leads to the development of resistance. We generated two multi anti-androgen resistant cell-line models by treatment of LNCaP cells with enzalutamid...
ORGANISM(S): Homo sapiens 
2019-09-26 | GSE130534 | GEO
UnknownMechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer.
Not available
S-EPMC7146610 | biostudies-literature
UnknownTRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.
Not available
S-EPMC5833828 | biostudies-literature
GenomicsDual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer elicits improved anti-tumor efficacy and apoptosis
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer elicits improved anti-tumor efficacy and apoptosis
PRJNA1028539 | ENA
UnknownDetermination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Not available
S-EPMC11075733 | biostudies-literature
UnknownIdentification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.
Not available
S-EPMC6787950 | biostudies-literature
Sort   by:  
 Page size